nodes	percent_of_prediction	percent_of_DWPC	metapath
Terbinafine—CYP1A2—Carmustine—lymphatic system cancer	0.186	0.289	CbGbCtD
Terbinafine—CYP2C19—Teniposide—lymphatic system cancer	0.135	0.211	CbGbCtD
Terbinafine—CYP2C9—Teniposide—lymphatic system cancer	0.112	0.175	CbGbCtD
Terbinafine—CYP3A4—Cytarabine—lymphatic system cancer	0.0663	0.103	CbGbCtD
Terbinafine—CYP3A4—Teniposide—lymphatic system cancer	0.0653	0.102	CbGbCtD
Terbinafine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0457	0.0712	CbGbCtD
Terbinafine—CYP3A4—Vincristine—lymphatic system cancer	0.0315	0.049	CbGbCtD
Terbinafine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00127	0.00355	CcSEcCtD
Terbinafine—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00127	0.00355	CcSEcCtD
Terbinafine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00127	0.00355	CcSEcCtD
Terbinafine—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00127	0.00354	CcSEcCtD
Terbinafine—Rash—Mechlorethamine—lymphatic system cancer	0.00126	0.00352	CcSEcCtD
Terbinafine—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00126	0.00352	CcSEcCtD
Terbinafine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00126	0.00352	CcSEcCtD
Terbinafine—Weight decreased—Vincristine—lymphatic system cancer	0.00126	0.00352	CcSEcCtD
Terbinafine—Anorexia—Fludarabine—lymphatic system cancer	0.00124	0.00345	CcSEcCtD
Terbinafine—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00123	0.00343	CcSEcCtD
Terbinafine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00122	0.0034	CcSEcCtD
Terbinafine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00121	0.00337	CcSEcCtD
Terbinafine—Skin discolouration—Methotrexate—lymphatic system cancer	0.00119	0.00333	CcSEcCtD
Terbinafine—Nausea—Mechlorethamine—lymphatic system cancer	0.00119	0.00332	CcSEcCtD
Terbinafine—Alopecia—Bleomycin—lymphatic system cancer	0.00118	0.0033	CcSEcCtD
Terbinafine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00118	0.0033	CcSEcCtD
Terbinafine—Jaundice—Mitoxantrone—lymphatic system cancer	0.00118	0.00329	CcSEcCtD
Terbinafine—Urticaria—Teniposide—lymphatic system cancer	0.00117	0.00327	CcSEcCtD
Terbinafine—Abdominal pain—Teniposide—lymphatic system cancer	0.00117	0.00326	CcSEcCtD
Terbinafine—Body temperature increased—Teniposide—lymphatic system cancer	0.00117	0.00326	CcSEcCtD
Terbinafine—Erythema—Bleomycin—lymphatic system cancer	0.00117	0.00325	CcSEcCtD
Terbinafine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00116	0.00325	CcSEcCtD
Terbinafine—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00116	0.00325	CcSEcCtD
Terbinafine—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00115	0.00321	CcSEcCtD
Terbinafine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00114	0.00319	CcSEcCtD
Terbinafine—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00114	0.00318	CcSEcCtD
Terbinafine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00113	0.00315	CcSEcCtD
Terbinafine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00113	0.00315	CcSEcCtD
Terbinafine—Visual impairment—Carmustine—lymphatic system cancer	0.00113	0.00314	CcSEcCtD
Terbinafine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00112	0.00313	CcSEcCtD
Terbinafine—Fatigue—Fludarabine—lymphatic system cancer	0.00112	0.00312	CcSEcCtD
Terbinafine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00111	0.0031	CcSEcCtD
Terbinafine—Pain—Fludarabine—lymphatic system cancer	0.00111	0.0031	CcSEcCtD
Terbinafine—Vasculitis—Methotrexate—lymphatic system cancer	0.0011	0.00308	CcSEcCtD
Terbinafine—Connective tissue disorder—Vincristine—lymphatic system cancer	0.0011	0.00306	CcSEcCtD
Terbinafine—Eye disorder—Carmustine—lymphatic system cancer	0.00109	0.00305	CcSEcCtD
Terbinafine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00109	0.00304	CcSEcCtD
Terbinafine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00109	0.00303	CcSEcCtD
Terbinafine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00108	0.00302	CcSEcCtD
Terbinafine—Anaemia—Bleomycin—lymphatic system cancer	0.00108	0.00301	CcSEcCtD
Terbinafine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00107	0.00298	CcSEcCtD
Terbinafine—Asthenia—Teniposide—lymphatic system cancer	0.00106	0.00296	CcSEcCtD
Terbinafine—Malaise—Bleomycin—lymphatic system cancer	0.00105	0.00293	CcSEcCtD
Terbinafine—Pruritus—Teniposide—lymphatic system cancer	0.00104	0.00292	CcSEcCtD
Terbinafine—Alopecia—Carmustine—lymphatic system cancer	0.00103	0.00288	CcSEcCtD
Terbinafine—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00103	0.00287	CcSEcCtD
Terbinafine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00103	0.00286	CcSEcCtD
Terbinafine—Mental disorder—Carmustine—lymphatic system cancer	0.00102	0.00286	CcSEcCtD
Terbinafine—Erythema—Carmustine—lymphatic system cancer	0.00102	0.00284	CcSEcCtD
Terbinafine—Cough—Bleomycin—lymphatic system cancer	0.00102	0.00284	CcSEcCtD
Terbinafine—Angiopathy—Vincristine—lymphatic system cancer	0.00101	0.00283	CcSEcCtD
Terbinafine—Diarrhoea—Teniposide—lymphatic system cancer	0.00101	0.00282	CcSEcCtD
Terbinafine—Chest pain—Bleomycin—lymphatic system cancer	0.000992	0.00277	CcSEcCtD
Terbinafine—Myalgia—Bleomycin—lymphatic system cancer	0.000992	0.00277	CcSEcCtD
Terbinafine—Alopecia—Vincristine—lymphatic system cancer	0.000986	0.00275	CcSEcCtD
Terbinafine—Discomfort—Bleomycin—lymphatic system cancer	0.00098	0.00274	CcSEcCtD
Terbinafine—Mental disorder—Vincristine—lymphatic system cancer	0.000977	0.00273	CcSEcCtD
Terbinafine—Alopecia—Mitoxantrone—lymphatic system cancer	0.00096	0.00268	CcSEcCtD
Terbinafine—Confusional state—Bleomycin—lymphatic system cancer	0.000959	0.00268	CcSEcCtD
Terbinafine—Vision blurred—Carmustine—lymphatic system cancer	0.000959	0.00268	CcSEcCtD
Terbinafine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000956	0.00267	CcSEcCtD
Terbinafine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000951	0.00266	CcSEcCtD
Terbinafine—Erythema—Mitoxantrone—lymphatic system cancer	0.000946	0.00264	CcSEcCtD
Terbinafine—Infection—Bleomycin—lymphatic system cancer	0.000945	0.00264	CcSEcCtD
Terbinafine—Anaemia—Carmustine—lymphatic system cancer	0.00094	0.00263	CcSEcCtD
Terbinafine—Vomiting—Teniposide—lymphatic system cancer	0.000938	0.00262	CcSEcCtD
Terbinafine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000931	0.0026	CcSEcCtD
Terbinafine—Asthenia—Fludarabine—lymphatic system cancer	0.000931	0.0026	CcSEcCtD
Terbinafine—Rash—Teniposide—lymphatic system cancer	0.00093	0.0026	CcSEcCtD
Terbinafine—Dermatitis—Teniposide—lymphatic system cancer	0.00093	0.0026	CcSEcCtD
Terbinafine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000926	0.00259	CcSEcCtD
Terbinafine—Headache—Teniposide—lymphatic system cancer	0.000925	0.00258	CcSEcCtD
Terbinafine—Pruritus—Fludarabine—lymphatic system cancer	0.000918	0.00256	CcSEcCtD
Terbinafine—Anorexia—Bleomycin—lymphatic system cancer	0.000906	0.00253	CcSEcCtD
Terbinafine—Anaemia—Vincristine—lymphatic system cancer	0.000897	0.00251	CcSEcCtD
Terbinafine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000891	0.00249	CcSEcCtD
Terbinafine—Photosensitivity—Methotrexate—lymphatic system cancer	0.000891	0.00249	CcSEcCtD
Terbinafine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000887	0.00248	CcSEcCtD
Terbinafine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000877	0.00245	CcSEcCtD
Terbinafine—Nausea—Teniposide—lymphatic system cancer	0.000877	0.00245	CcSEcCtD
Terbinafine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000874	0.00244	CcSEcCtD
Terbinafine—Vertigo—Vincristine—lymphatic system cancer	0.000872	0.00244	CcSEcCtD
Terbinafine—Hepatic failure—Methotrexate—lymphatic system cancer	0.00087	0.00243	CcSEcCtD
Terbinafine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000866	0.00242	CcSEcCtD
Terbinafine—Myalgia—Carmustine—lymphatic system cancer	0.000866	0.00242	CcSEcCtD
Terbinafine—Chest pain—Carmustine—lymphatic system cancer	0.000866	0.00242	CcSEcCtD
Terbinafine—Anxiety—Carmustine—lymphatic system cancer	0.000863	0.00241	CcSEcCtD
Terbinafine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000854	0.00238	CcSEcCtD
Terbinafine—Malaise—Mitoxantrone—lymphatic system cancer	0.000853	0.00238	CcSEcCtD
Terbinafine—Confusional state—Carmustine—lymphatic system cancer	0.000837	0.00234	CcSEcCtD
Terbinafine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000829	0.00232	CcSEcCtD
Terbinafine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000827	0.00231	CcSEcCtD
Terbinafine—Myalgia—Vincristine—lymphatic system cancer	0.000827	0.00231	CcSEcCtD
Terbinafine—Visual disturbance—Methotrexate—lymphatic system cancer	0.000826	0.00231	CcSEcCtD
Terbinafine—Cough—Mitoxantrone—lymphatic system cancer	0.000825	0.0023	CcSEcCtD
Terbinafine—Infection—Carmustine—lymphatic system cancer	0.000825	0.0023	CcSEcCtD
Terbinafine—Vomiting—Fludarabine—lymphatic system cancer	0.000825	0.0023	CcSEcCtD
Terbinafine—Rash—Fludarabine—lymphatic system cancer	0.000818	0.00228	CcSEcCtD
Terbinafine—Dermatitis—Fludarabine—lymphatic system cancer	0.000817	0.00228	CcSEcCtD
Terbinafine—Pain—Bleomycin—lymphatic system cancer	0.000813	0.00227	CcSEcCtD
Terbinafine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000813	0.00227	CcSEcCtD
Terbinafine—Headache—Fludarabine—lymphatic system cancer	0.000813	0.00227	CcSEcCtD
Terbinafine—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000808	0.00226	CcSEcCtD
Terbinafine—Myalgia—Mitoxantrone—lymphatic system cancer	0.000805	0.00225	CcSEcCtD
Terbinafine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000805	0.00225	CcSEcCtD
Terbinafine—Chest pain—Mitoxantrone—lymphatic system cancer	0.000805	0.00225	CcSEcCtD
Terbinafine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000802	0.00224	CcSEcCtD
Terbinafine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000795	0.00222	CcSEcCtD
Terbinafine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000792	0.00221	CcSEcCtD
Terbinafine—Anorexia—Carmustine—lymphatic system cancer	0.000791	0.00221	CcSEcCtD
Terbinafine—Infection—Vincristine—lymphatic system cancer	0.000787	0.0022	CcSEcCtD
Terbinafine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000784	0.00219	CcSEcCtD
Terbinafine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000778	0.00217	CcSEcCtD
Terbinafine—Nervous system disorder—Vincristine—lymphatic system cancer	0.000777	0.00217	CcSEcCtD
Terbinafine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000776	0.00217	CcSEcCtD
Terbinafine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000772	0.00216	CcSEcCtD
Terbinafine—Nausea—Fludarabine—lymphatic system cancer	0.00077	0.00215	CcSEcCtD
Terbinafine—Infection—Mitoxantrone—lymphatic system cancer	0.000767	0.00214	CcSEcCtD
Terbinafine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000756	0.00211	CcSEcCtD
Terbinafine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000756	0.00211	CcSEcCtD
Terbinafine—Urticaria—Bleomycin—lymphatic system cancer	0.000755	0.00211	CcSEcCtD
Terbinafine—Anorexia—Vincristine—lymphatic system cancer	0.000755	0.00211	CcSEcCtD
Terbinafine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000752	0.0021	CcSEcCtD
Terbinafine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00075	0.00209	CcSEcCtD
Terbinafine—Paraesthesia—Carmustine—lymphatic system cancer	0.000745	0.00208	CcSEcCtD
Terbinafine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000736	0.00205	CcSEcCtD
Terbinafine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000722	0.00202	CcSEcCtD
Terbinafine—Decreased appetite—Carmustine—lymphatic system cancer	0.000722	0.00202	CcSEcCtD
Terbinafine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000717	0.002	CcSEcCtD
Terbinafine—Paraesthesia—Vincristine—lymphatic system cancer	0.000712	0.00199	CcSEcCtD
Terbinafine—Pain—Carmustine—lymphatic system cancer	0.00071	0.00198	CcSEcCtD
Terbinafine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000704	0.00197	CcSEcCtD
Terbinafine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000703	0.00196	CcSEcCtD
Terbinafine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000701	0.00196	CcSEcCtD
Terbinafine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000693	0.00194	CcSEcCtD
Terbinafine—Decreased appetite—Vincristine—lymphatic system cancer	0.000689	0.00192	CcSEcCtD
Terbinafine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000684	0.00191	CcSEcCtD
Terbinafine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000684	0.00191	CcSEcCtD
Terbinafine—Fatigue—Vincristine—lymphatic system cancer	0.000683	0.00191	CcSEcCtD
Terbinafine—Asthenia—Bleomycin—lymphatic system cancer	0.000682	0.00191	CcSEcCtD
Terbinafine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000679	0.0019	CcSEcCtD
Terbinafine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000679	0.0019	CcSEcCtD
Terbinafine—Pain—Vincristine—lymphatic system cancer	0.000678	0.00189	CcSEcCtD
Terbinafine—Pruritus—Bleomycin—lymphatic system cancer	0.000673	0.00188	CcSEcCtD
Terbinafine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000671	0.00187	CcSEcCtD
Terbinafine—Eosinophilia—Methotrexate—lymphatic system cancer	0.000669	0.00187	CcSEcCtD
Terbinafine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000665	0.00186	CcSEcCtD
Terbinafine—Pancreatitis—Methotrexate—lymphatic system cancer	0.000663	0.00185	CcSEcCtD
Terbinafine—Pain—Mitoxantrone—lymphatic system cancer	0.00066	0.00184	CcSEcCtD
Terbinafine—Abdominal pain—Carmustine—lymphatic system cancer	0.000656	0.00183	CcSEcCtD
Terbinafine—Body temperature increased—Carmustine—lymphatic system cancer	0.000656	0.00183	CcSEcCtD
Terbinafine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000648	0.00181	CcSEcCtD
Terbinafine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000648	0.00181	CcSEcCtD
Terbinafine—Pancytopenia—Methotrexate—lymphatic system cancer	0.000642	0.00179	CcSEcCtD
Terbinafine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000636	0.00178	CcSEcCtD
Terbinafine—Neutropenia—Methotrexate—lymphatic system cancer	0.000632	0.00177	CcSEcCtD
Terbinafine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000631	0.00176	CcSEcCtD
Terbinafine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000628	0.00175	CcSEcCtD
Terbinafine—Abdominal pain—Vincristine—lymphatic system cancer	0.000626	0.00175	CcSEcCtD
Terbinafine—Body temperature increased—Vincristine—lymphatic system cancer	0.000626	0.00175	CcSEcCtD
Terbinafine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000617	0.00172	CcSEcCtD
Terbinafine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000613	0.00171	CcSEcCtD
Terbinafine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000612	0.00171	CcSEcCtD
Terbinafine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00061	0.0017	CcSEcCtD
Terbinafine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00061	0.0017	CcSEcCtD
Terbinafine—Vomiting—Bleomycin—lymphatic system cancer	0.000605	0.00169	CcSEcCtD
Terbinafine—Infestation—Methotrexate—lymphatic system cancer	0.000603	0.00168	CcSEcCtD
Terbinafine—Infestation NOS—Methotrexate—lymphatic system cancer	0.000603	0.00168	CcSEcCtD
Terbinafine—Rash—Bleomycin—lymphatic system cancer	0.0006	0.00167	CcSEcCtD
Terbinafine—Dermatitis—Bleomycin—lymphatic system cancer	0.000599	0.00167	CcSEcCtD
Terbinafine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000598	0.00167	CcSEcCtD
Terbinafine—Asthenia—Carmustine—lymphatic system cancer	0.000596	0.00166	CcSEcCtD
Terbinafine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000584	0.00163	CcSEcCtD
Terbinafine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00057	0.00159	CcSEcCtD
Terbinafine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000569	0.00159	CcSEcCtD
Terbinafine—Asthenia—Vincristine—lymphatic system cancer	0.000569	0.00159	CcSEcCtD
Terbinafine—Diarrhoea—Carmustine—lymphatic system cancer	0.000568	0.00159	CcSEcCtD
Terbinafine—Nausea—Bleomycin—lymphatic system cancer	0.000565	0.00158	CcSEcCtD
Terbinafine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000563	0.00157	CcSEcCtD
Terbinafine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000554	0.00155	CcSEcCtD
Terbinafine—Dizziness—Carmustine—lymphatic system cancer	0.000549	0.00153	CcSEcCtD
Terbinafine—Diarrhoea—Vincristine—lymphatic system cancer	0.000542	0.00151	CcSEcCtD
Terbinafine—Hepatitis—Methotrexate—lymphatic system cancer	0.000541	0.00151	CcSEcCtD
Terbinafine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000528	0.00147	CcSEcCtD
Terbinafine—Vomiting—Carmustine—lymphatic system cancer	0.000528	0.00147	CcSEcCtD
Terbinafine—Dizziness—Vincristine—lymphatic system cancer	0.000524	0.00146	CcSEcCtD
Terbinafine—Rash—Carmustine—lymphatic system cancer	0.000523	0.00146	CcSEcCtD
Terbinafine—Dermatitis—Carmustine—lymphatic system cancer	0.000523	0.00146	CcSEcCtD
Terbinafine—Visual impairment—Methotrexate—lymphatic system cancer	0.000522	0.00146	CcSEcCtD
Terbinafine—Headache—Carmustine—lymphatic system cancer	0.00052	0.00145	CcSEcCtD
Terbinafine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000512	0.00143	CcSEcCtD
Terbinafine—Eye disorder—Methotrexate—lymphatic system cancer	0.000506	0.00141	CcSEcCtD
Terbinafine—Tinnitus—Methotrexate—lymphatic system cancer	0.000505	0.00141	CcSEcCtD
Terbinafine—Vomiting—Vincristine—lymphatic system cancer	0.000504	0.00141	CcSEcCtD
Terbinafine—Rash—Vincristine—lymphatic system cancer	0.0005	0.0014	CcSEcCtD
Terbinafine—Dermatitis—Vincristine—lymphatic system cancer	0.000499	0.00139	CcSEcCtD
Terbinafine—Headache—Vincristine—lymphatic system cancer	0.000496	0.00139	CcSEcCtD
Terbinafine—Nausea—Carmustine—lymphatic system cancer	0.000493	0.00138	CcSEcCtD
Terbinafine—Angiopathy—Methotrexate—lymphatic system cancer	0.000491	0.00137	CcSEcCtD
Terbinafine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000491	0.00137	CcSEcCtD
Terbinafine—Immune system disorder—Methotrexate—lymphatic system cancer	0.000489	0.00137	CcSEcCtD
Terbinafine—Rash—Mitoxantrone—lymphatic system cancer	0.000487	0.00136	CcSEcCtD
Terbinafine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000486	0.00136	CcSEcCtD
Terbinafine—Headache—Mitoxantrone—lymphatic system cancer	0.000483	0.00135	CcSEcCtD
Terbinafine—Alopecia—Methotrexate—lymphatic system cancer	0.000478	0.00134	CcSEcCtD
Terbinafine—Mental disorder—Methotrexate—lymphatic system cancer	0.000474	0.00132	CcSEcCtD
Terbinafine—Erythema—Methotrexate—lymphatic system cancer	0.000471	0.00132	CcSEcCtD
Terbinafine—Nausea—Vincristine—lymphatic system cancer	0.000471	0.00131	CcSEcCtD
Terbinafine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000461	0.00129	CcSEcCtD
Terbinafine—Nausea—Mitoxantrone—lymphatic system cancer	0.000458	0.00128	CcSEcCtD
Terbinafine—Vision blurred—Methotrexate—lymphatic system cancer	0.000444	0.00124	CcSEcCtD
Terbinafine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000437	0.00122	CcSEcCtD
Terbinafine—Anaemia—Methotrexate—lymphatic system cancer	0.000435	0.00122	CcSEcCtD
Terbinafine—Malaise—Methotrexate—lymphatic system cancer	0.000425	0.00119	CcSEcCtD
Terbinafine—Vertigo—Methotrexate—lymphatic system cancer	0.000423	0.00118	CcSEcCtD
Terbinafine—Cough—Methotrexate—lymphatic system cancer	0.000411	0.00115	CcSEcCtD
Terbinafine—Arthralgia—Methotrexate—lymphatic system cancer	0.000401	0.00112	CcSEcCtD
Terbinafine—Chest pain—Methotrexate—lymphatic system cancer	0.000401	0.00112	CcSEcCtD
Terbinafine—Myalgia—Methotrexate—lymphatic system cancer	0.000401	0.00112	CcSEcCtD
Terbinafine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000398	0.00111	CcSEcCtD
Terbinafine—Discomfort—Methotrexate—lymphatic system cancer	0.000396	0.00111	CcSEcCtD
Terbinafine—Confusional state—Methotrexate—lymphatic system cancer	0.000388	0.00108	CcSEcCtD
Terbinafine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000384	0.00107	CcSEcCtD
Terbinafine—Infection—Methotrexate—lymphatic system cancer	0.000382	0.00107	CcSEcCtD
Terbinafine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000377	0.00105	CcSEcCtD
Terbinafine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000376	0.00105	CcSEcCtD
Terbinafine—Skin disorder—Methotrexate—lymphatic system cancer	0.000373	0.00104	CcSEcCtD
Terbinafine—Anorexia—Methotrexate—lymphatic system cancer	0.000367	0.00102	CcSEcCtD
Terbinafine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00035	0.000978	CcSEcCtD
Terbinafine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000345	0.000964	CcSEcCtD
Terbinafine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000338	0.000945	CcSEcCtD
Terbinafine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000334	0.000933	CcSEcCtD
Terbinafine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000332	0.000927	CcSEcCtD
Terbinafine—Fatigue—Methotrexate—lymphatic system cancer	0.000331	0.000926	CcSEcCtD
Terbinafine—Pain—Methotrexate—lymphatic system cancer	0.000329	0.000918	CcSEcCtD
Terbinafine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000317	0.000885	CcSEcCtD
Terbinafine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000314	0.000878	CcSEcCtD
Terbinafine—Urticaria—Methotrexate—lymphatic system cancer	0.000305	0.000853	CcSEcCtD
Terbinafine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000304	0.000849	CcSEcCtD
Terbinafine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000304	0.000849	CcSEcCtD
Terbinafine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000283	0.000791	CcSEcCtD
Terbinafine—Asthenia—Methotrexate—lymphatic system cancer	0.000276	0.00077	CcSEcCtD
Terbinafine—Pruritus—Methotrexate—lymphatic system cancer	0.000272	0.00076	CcSEcCtD
Terbinafine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000263	0.000735	CcSEcCtD
Terbinafine—Dizziness—Methotrexate—lymphatic system cancer	0.000254	0.00071	CcSEcCtD
Terbinafine—Vomiting—Methotrexate—lymphatic system cancer	0.000244	0.000683	CcSEcCtD
Terbinafine—Rash—Methotrexate—lymphatic system cancer	0.000242	0.000677	CcSEcCtD
Terbinafine—Dermatitis—Methotrexate—lymphatic system cancer	0.000242	0.000676	CcSEcCtD
Terbinafine—Headache—Methotrexate—lymphatic system cancer	0.000241	0.000673	CcSEcCtD
Terbinafine—Nausea—Methotrexate—lymphatic system cancer	0.000228	0.000638	CcSEcCtD
